Netherlands· NL-012b8c74a58c

Thiotepa Riemser 15 mg poeder voor concentraat voor oplossing voor infusie

A thiotepa product containing thiotepa, registered in Netherlands by Riemser Pharma GmbH. The same ATC class is registered in 16 of our 19 countries.

ATC L01AC01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about thiotepaAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Thiotepa is registered in 16 of 19 countries.

Countries holding a registration under ATC L01AC01 (thiotepa), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search thiotepa products by name

Thiotepa · ATC L01AC01

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: THIOTEPA
Manufacturer: Riemser Pharma GmbH
Country: Netherlands (NL)
ATC code: L01AC01
ATC class: Thiotepa
Defined daily dose: 1.62 g, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/21/1536

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

202 interactions on record for thiotepa.

Graded by severity as the source publishes them — 43 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check thiotepa against other medicines How interaction checks work

Thiotepa · interactions on record

202 records

43 severe
105 moderate
14 minor
40 info

Most severe, free to view

Nalidixic acidJ01MB02severe
CyclophosphamideL01AA01severe
ChlorambucilL01AA02severe
MelphalanL01AA03severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Thiotepa in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All thiotepa products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

Austria · Thiotepa Fresenius Kabi
Belgium · Thiotepa Fresenius Kabi
Bulgaria · Тиотепа Msn
Czechia · Thiotepa Fresenius Kabi, Thiotepa Msn
Germany · Thionovia, Thiotepa Fresenius Kabi
Denmark · Thiotepa Abcur, Thiotepa Fresenius Kabi
Estonia · Thiotepa Fresenius Kabi, Thiotepa Msn
Spain · Thionovia, Thiotepa Vivanta
Finland · Thiotepa Abcur, Thiotepa Fresenius Kabi
France · Thionovia, Thiotepa Fresenius Kabi
United Kingdom (Northern Ireland) · Thiotepa, Thiotepa Hikma Farmacêutica (Portugal)
Croatia · Tiotepa Fresenius Kabi, Tiotepa Msn
Hungary · Thiotepa, Thiotepa Medac
Ireland · Thiotepa Fresenius Kabi
Iceland · Tepadina, Thiotepa Abcur
Italy · Thionovia, Thiotepa Medac
Liechtenstein · Tepadina, Thiotepa Riemser
Lithuania · Thiotepa Fresenius Kabi, Thiotepa Msn
Latvia · Thiotepa Fresenius Kabi, Thiotepa Msn
Norway · Tepadina, Thiotepa Abcur
Poland · Thiotepa Fresenius Kabi, Thiotepa Msn
Portugal · Tiotepa Fresenius Kabi, Tiotepa Hikma
Romania · Thiotepa Fresenius Kabi, Thiotepa Msn
Sweden · Thionovia, Thiotepa Abcur
Slovenia · Thiotepa Msn
Slovakia · Thiotepa Fresenius Kabi, Thiotepa Msn

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/e88713b2-1cde-4e7a-a498-0866d3845428
GET /v1/drugs/e88713b2-1cde-4e7a-a498-0866d3845428?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/thiotepa-riemser-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Thiotepa",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126542",
  "excipients": [
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "THIOTEPA"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/03/26",
  "procedure_number": "EMEA/H/C/005434",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/21/1536",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about thiotepa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console